Search clinical trials for: panitumumab,

Total 264 results

Pfizer

Completed

Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors

Metastatic Colorectal Cancer

Belgium, Canada, France, Spain, United States, Italy, Netherlands
University of Alabama at Birmingham

Recruiting

Phase II Panitumumab-IRDye800 in Head & Neck Cancer

Head and Neck Cancer

United States
Northwestern University
GlaxoSmithKline

Completed

Histological Characterization and Differentiation of Rash From Other Epidermal Growth Factor Receptor (EGFR) Inhibitors

Skin Rash

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Recruiting

Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients With Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Squamous Cell Carcinoma

United States
AIO-Studien-gGmbH

Completed

Comparison of Two Preemptive Treatment Strategies of Panitumumab Mediated Skin Toxicity and Assessment of QoL in Patient With Ras-wt Colorectal Cancer

Ras-wildtype Colorectal Cancer

Germany
Takeda

Completed

A Phase I/II Study for the Safety and Efficacy of Panitumumab in Combination With TAS-102 for Patients With Colorectal Cancer (APOLLON)

Colorectal Cancer

Japan
Takeda

Active, not recruiting

An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of mFOLFOX6 + Bevacizumab Versus mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-naïve Unresectable Advanced or Recurrent Colorectal Cancer

Colorectal Cancer

Japan
Takeda

Completed

Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC (PARADIGM)

Colorectal Cancer

Japan
Radboud University Medical Center

Terminated

Radio-chemotherapy With or Without Panitumumab (Vectibix®) in Irresectable Squamous Cell Carcinoma or Adenocarcinoma of the Oesophagus (PANORAMIC)

Irresectable Squamous Cell or Adenocarcinoma of the Oesophagus

Netherlands
WiSP Wissenschaftlicher Service Pharma GmbH
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH

Terminated

PURO Panitumumab in Combination With Gemcitabine/Cisplatin in Advanced Urothelial Cancer (PURO)

Urinary Bladder Cancer

Germany
Spanish Cooperative Group for the Treatment of...
Amgen

Completed

Safety and Efficacy Study of FOLFOX4+Panitumumab vs.FOLFIRI+Panitumumab in Subjects WT KRAS Colorectal Cancer and Liver-only Metastases (PLANET)

Colorectal Cancer

Spain
Amgen

Completed

Two Dose Schedules of Panitumumab in Subjects With Advanced Solid Tumors

Solid Tumors | Oncology | Tumors
Robert Ferris
Amgen

Completed

Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer

Head and Neck Cancer | Cancer of Head and Neck | Head Cancer | Neck Cancer | Neoplasms, Head and Neck | Cancer of the Head and Neck | Cancer of Neck | Upper Aerodigestive Tract Neoplasms | Neck Neoplasms | Cancer of the Head | Cancer of the Neck | UADT Neoplasms | Cancer of Head | Head Neoplasms | Head, Neck Neoplasms | Neoplasms, Head and other conditions

United States
Cliniques universitaires Saint-Luc- Université...

Terminated

Preoperative Panitumumab and Radiotherapy in Rectal Cancer (PrePaRad)

Rectal Cancer

Belgium
Gruppo Oncologico del Nord-Ovest

Completed

FOLFOXIRI Plus Panitumumab In Kras and Braf Wild-Type Metastatic Colorectal Cancer (TRIP)

Metastatic Colo-rectal Cancer

Italy
King Abdullah Medical City

Recruiting

Re-challenge Therapy With Chemotherapy & Panitumumab in Metastatic Colorectal Cancer Patients Treated With an Anti-EGFR (REPAN)

Metastatic Colorectal Cancer

Saudi Arabia
Hellenic Cooperative Oncology Group

Completed

Study of Panitumumab-Capecitabine-Oxaliplatin In Wild-Type K-Ras Metastatic Colorectal Cancer Patients

Colorectal Cancer

Greece
University of Utah

Terminated

Regorafenib + Panitumumab for Colorectal Cancers

KRAS and NRAS Wild-type Colorectal Cancer

United States
Amgen
ZeinCRO Hellas SA

Completed

Prospective Observational Study of 1st and 2nd Line Vectibix® Use in RAS-wt mCRC Pts to Evaluate Pattern of Use and ORR (VISION)

Metastatic Colorectal Cancer

Greece
Amgen

Completed

Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer

Rectal Cancer | Colon Cancer
Gruppo Oncologico del Nord-Ovest
Bayer; Amgen

Recruiting

PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence (PARERE)

Colorectal Cancer

Italy
Jonsson Comprehensive Cancer Center

Completed

Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer

Prostate Cancer

United States
Amgen

Completed

Safety and Efficacy Study of ABX-EGF in Patients With Renal Cancer, Part 2

Advanced Renal Cell Carcinoma
Amgen

Completed

Phase 2 Study of ABX-EGF (Panitumumab) in Japanese Subjects With M-colorectal Cancer

Metastatic Colorectal Cancer
Eben Rosenthal

Recruiting

Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Lung Carcinoma | Metastatic Malignant Neoplasm in the Lung

United States
Memorial Sloan Kettering Cancer Center
Amgen

Active, not recruiting

Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer

Metastatic Colorectal Cancer

United States
Andrei Iagaru
National Cancer Institute (NCI); National Institutes of Health (NIH)

Completed

Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer

Squamous Cell Carcinoma of the Head and Neck | Carcinoma of the Head and Neck

United States
Associacio catalana per a la recerca oncologica...
Amgen

Unknown

A Clinical Trial of Panitumumab in Combination With FOLFIRI Chemotherapy as Second Line Treatment in Subjects With Metastatic Colorectal Cancer Expressing Wild-type KRAS and Who Had Progressed ≥ 6 Months After the Last Dose of the First Line Chemotherapy (ACTIVE)

Metastatic Colorectal Cancer

Spain
Matteo's Friends

Recruiting

Dynamic Changes in Circulating Tumour Cells Protein Expression (Liquid-DRER2)

Recurrence Free Survival

Italy
University of Alabama at Birmingham

Recruiting

Comparison of 89Zr Panitumumab and (18)F-Fluorodeoxyglucose to Identify Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma

United States
Stanford University

Suspended

Pilot Study of 89-Zr Panitumumab in Pancreas Cancer

Pancreas Cancer

United States
University of Alabama at Birmingham

Withdrawn

Imaging With [89Zr]Panitumumab-PET/MRI in Patients With Newly Diagnosed Colorectal Cancer (Panitumumab)

Metastatic Colon Cancer

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer

Kidney Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Lung Cancer | Prostate Cancer

United States
Takeda

Recruiting

An Additional Analysis of Data From the PARADIGM Exploratory Study (NCT02394834) in Patients With Advanced/Recurrent Colorectal Cancer

Colorectal Cancer

Japan
Amgen

Completed

Observational Study of Vectibix With Chemotherapy for Metastatic Colorectal Cancer Patients

Wild-type RAS Metastatic Colorectal Cancer
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy in Treating Patients With Metastatic Colorectal Cancer

Colorectal Cancer

United States
Spanish Cooperative Group for the Treatment of...
Amgen

Completed

Panitumumab in Combination With Irinotecan Chemotherapy as 2nd-line Therapy in Subjects With mCRC

Metastatic Colorectal Cancer

Spain
Athanassios Argiris
University of Pittsburgh; University of North Carolina, Chapel Hill

Withdrawn

Postoperative Radiotherapy and Panitumumab in High-Risk Salivary Gland Malignancies

Salivary Gland Malignancy

United States
Federation Francophone de Cancerologie Digestive

Completed

Radiochemotherapy With Panitumumab in the Localised Epidermoid Carcinoma of the Anus

Epidermoid Carcinoma | Anus

France
Eben Rosenthal

Completed

Panitumumab IRDye800 Optical Imaging Study

Head and Neck Cancer

United States
Memorial Sloan Kettering Cancer Center
Genentech, Inc.

Completed

Vemurafenib and Panitumumab Combination Therapy in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

United States
Massachusetts General Hospital

Terminated

Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma (EOXP)

Gastric Adenocarcinoma | Esophageal Adenocarcinoma

United States
John Strickler, M.D.
Exelixis

Completed

Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal Cancer (CaboMAb)

Colorectal Cancer

United States
Amgen

Completed

Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment

Colorectal Cancer | Non-Small Cell Lung Cancer | Prostate Cancer | Solid Tumors | Advanced Renal Cell Carcinoma
Amgen

Withdrawn

Safety Evaluation of Panitumumab and Sirolimus in Advanced Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | Oncology
Andrei Iagaru

Not yet recruiting

Study Evaluating Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in Head and Neck Squamous Cell Carcinoma

Head-and-neck Squamous Cell Carcinoma

United States
Federation Francophone de Cancerologie Digestive
Amgen

Active, not recruiting

FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation (OPTIPRIME)

Metastatic Colorectal Cancer

France, Martinique
Massachusetts General Hospital
Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Amgen

Completed

Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer

Colorectal Cancer

United States
Fondazione IRCCS Istituto Nazionale dei Tumori,...

Unknown

Panitumumab-based Maintenance in Patients With RAS Wild-type, Metastatic Colorectal Cancer (Valentino) (Valentino)

Metastatic Colorectal Cancer

Italy
Spanish Cooperative Group for the Treatment of...

Completed

Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques (ULTRA)

Stage IV Colorectal Cancer

Spain

3

Subscribe